Metabolomics is the study of small compounds, often known as metabolites, in cells, biofluids, tissues, and organisms on a massive scale. The metabolome refers to the collection of small molecules and their interactions inside a biological system. Metabolomics, or the comprehensive examination of metabolites in a biological system, is a new technology that has the potential to revolutionise precision medicine. Small quantities of metabolites have traditionally been utilised to detect complex metabolic diseases as well as monogenic disorders such inborn metabolic abnormalities. Current metabolomic methods are capable of exact analysis of hundreds to thousands of metabolites, much exceeding the scope of typical clinical chemistry procedures. Metabolomics is a great tool for the pharmaceutical, preventative healthcare, and agricultural industries, among others, because of its non-invasive nature and close link to the phenotypic. We may be able to track the trends of our own metabolome for individualised medications and enhanced treatment techniques in the future, due to the availability of personalised metabolomics
Title : Why do 90% of the drugs fail in development? An analysis of 82+ submissions; and a case study of immunotherapy
Narendra Chirmule, Indian Institute of Technology (IIT), India
Title : Eliminating implant failure in humans with nano chemistry: 45,000 cases and counting
Thomas J Webster, Brown University, United States
Title : Evaluating cell compatibility and subcutaneous host response of silk fibroin–chitosan plug composites as potential resorbable implants
Luis Jesus Villarreal Gomez, Universidad Autonoma de Baja California, Mexico
Title : Steps and strides: Cross-species insights into movement and injury
Babak Faramarzi, Western University of Health Sciences, United States
Title : Ancient wisdom, modern science: Biotech services transforming ayurveda
Prashant Sakharam Bhokardankar, Datta Meghe Ayurvedic Medical College Hospital and Research Centre, India
Title : Scientist’s computational lawyer
Julia Sidorova, Instituto Carlos III de Salud (CIBER-EHD), Spain